Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela-Silva, Waldemar Baldoquín-Rodríguez, Marisel Martínez-Pérez, Meiby Rodríguez-González, Beatriz Paredes-Moreno, Ivis Mendoza-Hernández, Raúl González-Mujica, Oscar Samón-Tabio, Pablo Velazco-Villares, Juan Pablo Bacallao-Castillo, Ernesto Licea-Martín, Misladys Rodríguez-Ortega, Nuris Herrera-Marrero, Esperanza Caballero-González, Liudmila Egües-Torres, Reinaldo Duartes-González, Serguey García-Blanco, Suzette Pérez-Cabrera, Santos Huete-Ferreira, Kirenia Idalmis-Cisnero, Omayda Fonte-Galindo, Dania Meliá-Pérez, Ivonne Rojas-Remedios, Delaram Doroud, Mohammad Mehdi Gouya, Alireza Biglari, Patrick Van der Stuyft, Sonsire Fernández-Castillo, Yanet Climent-Ruiz, Yury Valdes-Balbín, Dagmar García-Rivera, Vicente Verez-Bencomo, the SOBERANA Phase 3 team
medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703
